Sei Investments Co. Acquires 24,658 Shares of GSK plc (NYSE:GSK)

Sei Investments Co. boosted its holdings in GSK plc (NYSE:GSK) by 3.1% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 831,592 shares of the pharmaceutical company’s stock after purchasing an additional 24,658 shares during the quarter. Sei Investments Co.’s holdings in GSK were worth $32,017,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in GSK. JTC Employer Solutions Trustee Ltd increased its holdings in GSK by 71.3% in the 1st quarter. JTC Employer Solutions Trustee Ltd now owns 21,141,012 shares of the pharmaceutical company’s stock valued at $909,063,000 after acquiring an additional 8,800,822 shares during the last quarter. Hsbc Holdings PLC bought a new stake in shares of GSK in the fourth quarter worth about $92,281,000. Armistice Capital LLC lifted its position in shares of GSK by 670.5% in the fourth quarter. Armistice Capital LLC now owns 2,196,000 shares of the pharmaceutical company’s stock worth $81,384,000 after buying an additional 1,911,000 shares in the last quarter. Primecap Management Co. CA boosted its stake in GSK by 13.9% during the second quarter. Primecap Management Co. CA now owns 14,511,390 shares of the pharmaceutical company’s stock valued at $558,689,000 after buying an additional 1,773,020 shares during the last quarter. Finally, Mondrian Investment Partners LTD grew its holdings in GSK by 37.8% during the 1st quarter. Mondrian Investment Partners LTD now owns 5,510,840 shares of the pharmaceutical company’s stock valued at $236,250,000 after buying an additional 1,512,442 shares in the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Stock Up 0.1 %

Shares of GSK opened at $40.86 on Tuesday. The firm has a fifty day moving average price of $41.43 and a 200-day moving average price of $41.66. The company has a current ratio of 0.82, a quick ratio of 0.54 and a debt-to-equity ratio of 0.99. The firm has a market capitalization of $84.67 billion, a P/E ratio of 14.80, a P/E/G ratio of 1.41 and a beta of 0.66. GSK plc has a 12-month low of $33.67 and a 12-month high of $45.92.

GSK (NYSE:GSK) last issued its earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09. The business had revenue of $9.95 billion for the quarter, compared to the consensus estimate of $9.49 billion. GSK had a net margin of 12.87% and a return on equity of 51.48%. Equities research analysts expect that GSK plc will post 4.15 earnings per share for the current year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 10th. Shareholders of record on Friday, August 16th will be issued a dividend of $0.3843 per share. This is an increase from GSK’s previous quarterly dividend of $0.38. This represents a $1.54 annualized dividend and a yield of 3.76%. The ex-dividend date is Friday, August 16th. GSK’s dividend payout ratio (DPR) is presently 54.71%.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. The Goldman Sachs Group began coverage on shares of GSK in a report on Thursday, May 30th. They issued a “neutral” rating and a $47.00 target price for the company. Barclays upgraded GSK to a “hold” rating in a research report on Tuesday, August 27th. Jefferies Financial Group raised their price objective on GSK from $52.50 to $53.00 and gave the company a “buy” rating in a research note on Tuesday, July 2nd. Berenberg Bank upgraded GSK to a “strong-buy” rating in a research report on Thursday, June 20th. Finally, UBS Group lowered shares of GSK from a “buy” rating to a “neutral” rating in a research note on Monday, July 8th. Four equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $50.00.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.